// App-Quantinova.ai

e16529 : Prediction of metastatic castrate-resistant prostate cancer response to abiraterone or enzalutamide by a baseline blood-based CTC gene expression signature.

Researchers

Presenter

  • Michael Joseph Lariviere

Principal Investigators

  • Naomi B. Haas

  • Yauheniya Cherkas

  • Karl Nielsen

  • Brad Foulk

  • Jaymala Patel

  • Denis Smirnov

  • David J. Vaughn

  • Ravi K. Amaravadi

  • Samantha L. Savitch

  • Krishna Majmundar

  • Thomas H. Buckingham

  • Stephanie S. Yee

  • Jeremy Jones

  • Sumanta K. Pal

  • Erica L. Carpenter

Medical Centers

  • University of Pennsylvania, Philadelphia, PA

  • Penn Medicine Abramson Cancer Center, Philadelphia, PA

  • Janssen Research and Development, LLC, Spring House, PA

  • Janssen Research and Development, LLC, Spring House, PA

  • Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA

  • City of Hope, Duarte, CA

  • City of Hope National Medical Center, Duarte, CA

  • University of Pennsylvania, Abramson Cancer Center, Philadelphia, PA

Locations

  • United States

Companies

  • JB Medical Ltd.

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Nephrology

Disease

  • N/A

Biomarkers

  • Circulating tumor cells

Drug/Treatment

  • Enzalutamide

  • CB-7598

  • Prednisone

Outcome

  • N/A

Study Design

  • Prospective

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved